TALOPH(SH:600222) Zhong Guo Zheng Quan Bao·2025-12-01 14:44Core Viewpoint - TaLong Pharmaceutical is undergoing a potential change in control due to the share transfer plan by its controlling shareholder, Zhengzhou TaiRong Industrial Investment Co., Ltd. [2] Group 1: Share Transfer and Control Change - Zhengzhou TaiRong Industrial Investment Co., Ltd. is planning to transfer shares, which may lead to a change in the company's control [2] - As of September 30, 2025, TaiRong holds 82.44 million shares, accounting for approximately 14.37% of the total shares, making it the largest shareholder [2] - The actual controller of TaLong Pharmaceutical is the Zhengzhou High-tech Zone Management Committee [2] Group 2: Financial Performance - For the first three quarters of 2025, TaLong Pharmaceutical reported revenue of 1.187 billion yuan, a year-on-year decrease of 11.47% [3] - The net profit attributable to the parent company for the same period was 25.3255 million yuan, down 12.36% year-on-year [3] - The decline in revenue is attributed to the ongoing standardization work for the company's main products in the national Chinese medicine procurement, which has not yet fully covered the market [3] Group 3: Business Operations and Strategy - TaLong Pharmaceutical's main business includes drug manufacturing and research services, focusing on Chinese medicine oral preparations and covering various therapeutic areas [3] - The company is actively working on the national Chinese medicine procurement process, with plans to manage inventory and supply chain effectively during the peak sales season for respiratory medications [4] - Strategies include enhancing supply chain management, controlling raw material costs, and expanding market share through multi-channel cooperation [4]